Cases
Significant Representations: Represented Electro-Science Laboratories, Inc. in its acquisition by Ferro Corporation, also involving the concurrent acquisition of Agmet Limited in the UK
the assets of their sister corporation in Shanghai, China.
Advised Venture Fundusz Inwestycyjny Zamkniety, managed by TFI Trigon S.A., in connection with the acquisition of a non-controlling stake in Seed Labs Inc., a U.S.-based corporation involved in the development of an end-to-end smart lighting platform using new transmission protocols.
Represented Amazon Ventures in a Series D investment in WhoSay, Inc.
Represented Consol Energy, Inc. in a $3.5 billion sale of Consolidation Coal Company to a subsidiary of Murray Energy Corporation.
Represented publicly traded Finnish manufacturing company in its acquisition of a division of a large U.S. company, including the purchase of stock
assets of subsidiaries located in the United States
five foreign countries,
the coordination of closings in different countries across different calendar years.
Represented multinational publicly traded Swedish manufacturing company in its acquisition of a division of a Fortune 500 company, including the purchase of stock
assets of subsidiaries located in 12 different countries.
Represented multinational publicly traded Indian company in the acquisition of a California corporation. The transaction included particularly complex regulatory matters specific to the defense industry as well as cross-border employee benefit issues.
Represented Nasdaq-traded CRO in the acquisition of a Finnish corporation for a combination of cash
stock. The transaction involved complex cross-border securities issues.
Represented Israel-based provider of application problem resolution software in its acquisition by a large U.S. software company, structuring
negotiating a complex stock purchase agreement that incorporated the use of a novel statutory take along provision.
Represented Israel-based leading manufacturer of armored equipment in its acquisition of a Michigan-based defense contractor.
Represented Mid-Atlantic late-stage venture fund in an investment in a rapidly exp
ing provider of medical market research.
Represented U.S.-based biotech company in a Series B round investment that was led by a Swiss-based, global life sciences fund
a leading California-based life sciences investment firm.
Represented Swiss-based, global life sciences fund in a Series B investment in a biotechnology company engaged in the development of novel products for the treatment of metabolic diseases.
Represented U.S.-based corporation engaged in the development of alternative energy sources in a significant investment by a leading Israeli private equity fund.
Represented Israeli-based biotech company in a worldwide license
distribution agreement with a leading Italian pharma company.
The above representations were h
led by Mr. Gitlin prior to his joining Greenberg Traurig, LLP .
